Independent association of HbA1c and nonalcoholic fatty liver disease in an elderly Chinese population

BMC Gastroenterology

Youming Li²  Min Miao¹  Chaohui Yu²  Lei Xu³  Chengfu Xu²  Han Ma² 

[1] Department of Internal Medicine, Zhenhai Lianhua Hospital, Ningbo, China;Department of Gastroenterology, the First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, China;Department of Gastroenterology, Ningbo No. 1 Hospital, Ningbo, China

关键词: Obesity;    Elderly;    Glycosylated hemoglobin;    Fatty liver;   

Others  :  858249
DOI  :  10.1186/1471-230X-13-3

 received in 2012-08-23, accepted in 2012-12-14,  发布年份 2013

【 摘 要 】

Background

To investigate the association between serum glycosylated hemoglobin (HbA1c) levels and nonalcoholic fatty liver disease (NAFLD) in an elderly Chinese population.

Methods

A cross-sectional study was performed among the 949 retired elderly employees of Zhenhai Refining & Chemical Company Ltd., Ningbo, China.

Results

A total of 257 (27.08%) subjects fulfilled the diagnostic criteria of NAFLD, and NAFLD patients had significantly higher serum HbA1c levels than controls (P <0.001). The prevalence of NAFLD was significantly higher in subjects with increased serum HbA1c level (HbA1c ≥6.5%) than in those with normal range of serum HbA1c level (51.71% vs. 25.20%; P <0.001), and the prevalence increased along with progressively higher serum HbA1c levels (P for trend <0.001). Stepwise logistic regression analysis showed that serum HbA1c level was significantly associated with the risk for NAFLD (odds ratio: 1.547, 95% confidence interval: 1.054 – 2.270; P =0.026).

Conclusions

Our results suggest that serum HbA1c level is associated with NAFLD, and increased serum HbA1c level is an independent risk factor for NAFLD in elderly Chinese.

【 授权许可】

   
2013 Ma et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Fan JG, Farrell GC: Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol 2009, 50(1):204-210.
• [2]Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140(1):124-131.
• [3]Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(S1):S99-S112.
• [4]Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129(1):113-121.
• [5]Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, et al.: The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005, 143(10):722-728.
• [6]Ryan MC, Wilson AM, Slavin J, Best JD, Jenkins AJ, Desmond PV: Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. Diabetes Care 2005, 28(5):1222-1224.
• [7]Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999, 84(5):1513-1517.
• [8]Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, Wasada T: Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005, 22(9):1141-1145.
• [9]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34(Suppl 1):62-69.
• [10]Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
• [11]Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R: Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006, 26(7):856-863.
• [12]Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL: Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012,  .
• [13]Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30(6):1356-1362.
• [14]Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI: Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010, 105(11):2389-2395.
• [15]Davidson MB, Schriger DL: Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 2010, 87(3):415-421.
• [16]Li Y, Xu C, Yu C, Xu L, Miao M: Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009, 50(5):1029-1034.
• [17]Xu C, Xu L, Yu C, Miao M, Li Y: Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clin Endocrinol (Oxf) 2011, 75(2):240-246.
• [18]Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY: Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese Journal of Hepatology 2010; 18:163–166). J Dig Dis 2011, 12(1):38-44.
• [19]Alberti KG, Zimmet P, Shaw J: Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469-480.
• [20]Yki-Järvinen H: Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. Dig Dis 2010, 28(1):203-209.
• [21]D'Adamo E, Giannini C, Chiavaroli V, de Giorgis T, Verrotti A, Chiarelli F, Mohn A: What is the significance of soluble and endogenous secretory receptor for advanced glycation end products in liver steatosis in obese prepubertal children? Antioxid Redox Signal 2011, 14(6):1167-1172.
• [22]Bian H, Yan H, Zeng M, Rao S, Yao X, Zhou J, Jia W, Gao X: Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol Ther 2011, 13(2):149-155.
• [23]Yki-Jarvinen H, Westerbacka J: The fatty liver and insulin resistance. Curr Mol Med 2005, 5(3):287-295.
• [24]Higgins PJ, Garlick RL, Bunn HF: Glycosylated hemoglobin in human and animal red cells: role of glucose permeability. Diabetes 1982, 31(9):743-748.
• [25]Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM: Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 2008, 57(9):2445-2452.
• [26]Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM: Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008, 44(7):1259-1272.
• [27]Otogawa K, Kinoshita K, Fujii H, Sakabe M, Shiga R, Nakatani K, Ikeda K, Nakajima Y, Ikura Y, Ueda M, et al.: Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007, 170(3):967-980.
• [28]Cazzola R, Rondanelli M, Russo-Volpe S, Ferrari E, Cestaro B: Decreased membrane fluidity and altered susceptibility to peroxidation and lipid composition in overweight and obese female erythrocytes. J Lipid Res 2004, 45(10):1846-1851.
• [29]Reeder BJ: The redox activity of hemoglobins: from physiologic functions to pathologic mechanisms. Antioxid Redox Signal 2010, 13(7):1087-1123.
• [30]Kung CM, Tseng ZL, Wang HL: Erythrocyte fragility increases with level of glycosylated hemoglobin in type 2 diabetic patients. Clin Hemorheol Microcirc 2009, 43(4):345-351.
• [31]Targher G, Arcaro G: Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007, 191(2):235.
• [32]Targher G, Marra F, Marchesini G: Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008, 51(11):1947-1953.
• [33]Adams RJ, Appleton SL, Hill CL, Wilson DH, Taylor AW, Chittleborough CR, Gill TK, Ruffin RE: Independent association of HbA(1c) and incident cardiovascular disease in people without diabetes. Obesity (Silver Spring) 2009, 17(3):559-563.
• [34]Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, Coresh J, Brancati FL: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010, 362(9):800-811.